An improved long-term sales target today revitalised GSK shares after their dismal 2024. The confidence in GSK’s drugs pipeline came alongside results pointing to top line growth between 3% and 5% in ...
GSK launched a rare £2bn share buyback and raised its growth targets on the back of strong sales of speciality medicines including cancer and HIV drugs, sending shares up as much as 6 per cent on ...
Feb. 1 Canada and Mexico both levied retaliatory tariffs on U.S. imports in response to Trump’s directive, while China said it would file a lawsuit with the World Trade Organization and take ...